CALTX.ST Stock - Calliditas Therapeutics AB (publ)
Unlock GoAI Insights for CALTX.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $1.21B | $802.88M | $229.35M | $874,000 | $184.83M |
| Gross Profit | $1.13B | $787.68M | $229.35M | $874,000 | $184.83M |
| Gross Margin | 93.6% | 98.1% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-384,397,000 | $-421,943,000 | $-524,456,000 | $-379,720,000 | $-28,019,000 |
| Net Income | $-466,185,000 | $-412,268,000 | $-509,537,000 | $-436,511,000 | $-32,578,000 |
| Net Margin | -38.6% | -51.3% | -222.2% | -49944.1% | -17.6% |
| EPS | $-8.69 | $-7.78 | $-10.02 | $-9.73 | $-0.88 |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Visit WebsiteEarnings History & Surprises
CALTX.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 21, 2025 | — | — | — | — |
Q1 2025 | Feb 20, 2025 | — | — | — | — |
Q4 2024 | Nov 11, 2024 | $-0.30 | — | — | — |
Q3 2024 | Aug 13, 2024 | $-0.30 | $-0.88 | -193.3% | ✗ MISS |
Q2 2024 | May 23, 2024 | $-1.64 | $-4.59 | -179.9% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $-1.73 | $-0.34 | +80.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.28 | $-3.14 | -1021.4% | ✗ MISS |
Q3 2023 | Aug 17, 2023 | $-2.15 | $-1.71 | +20.5% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-1.70 | $-3.49 | -105.3% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-1.71 | $-0.07 | +95.9% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-3.02 | $-0.17 | +94.4% | ✓ BEAT |
Q3 2022 | Aug 18, 2022 | $-4.23 | $-3.62 | +14.4% | ✓ BEAT |
Q2 2022 | May 18, 2022 | $-3.54 | $-3.95 | -11.5% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-3.72 | $-4.19 | -12.6% | ✗ MISS |
Q4 2021 | Nov 18, 2021 | — | $0.21 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-3.20 | — | — |
Q2 2021 | May 18, 2021 | — | $-2.51 | — | — |
Q1 2021 | Feb 18, 2021 | — | $-3.41 | — | — |
Q4 2020 | Nov 12, 2020 | — | $-2.77 | — | — |
Latest News
Frequently Asked Questions about CALTX.ST
What is CALTX.ST's current stock price?
What is the analyst price target for CALTX.ST?
What sector is Calliditas Therapeutics AB (publ) in?
What is CALTX.ST's market cap?
Does CALTX.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CALTX.ST for comparison